vasopressin - early initiation

ApprovedSmall molecule

vasopressin - early initiation is one of 25 small molecule programs targeting Septic Shock. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Septic ShockActive, not recruiting

Septic ShockApproved

Active, not recruiting

Competition

Competitive Landscape

224 competitors in Septic Shock

#DrugCompanyPhaseTrials

vasopressin - early initiation

TThe Cleveland Clinic

Approved

1 2

Primaxin

Pfizer

Preclinical

2 3

Intropin

Pfizer

Preclinical

2 4

Zyvox

Pfizer

Preclinical

1 5

Doribax

Spravato

2 7

Avastin

BBio-Thera Solutions

Preclinical

1 8

Cubicin

BBaxter Healthcare Corporation

Preclinical

1 9

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Glucophage

EMD Serono

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Septic Shock1 trial

Early Versus Late Adjunctive Vasopressin in Septic Shock

Recruiting·TThe Cleveland Clinic·Phase 4·NCT06709573·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for vasopressin - early initiation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — vasopressin - early initiation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for vasopressin - early initiation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Cleveland Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TThe Cleveland Clinic

vasopressin - early initiation

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Septic Shock1 trial

References

Drug Info

Quick Facts

Related News